AbbVie (ABBV) – StreetInsider.com Reports
-
AbbVie (ABBV) April weekly option implied volatility into quarter results
-
AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
-
AbbVie (ABBV) April weekly 167.50 straddle into quarter results
-
AbbVie (ABBV) Reports Phase 3 SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients With Giant Cell Arteritis
-
Q1 earnings buy list: Morgan Stanley picks Nvidia, Amazon and these 10 stocks
-
FDA: working with AbbVie (ABBV) to identify, investigate and remove suspected counterfeit Botox products found in the US
-
AbbVie (ABBV) Announces Data Supporting Long-Term Safety and Efficacy of Atogepant for Migraine
-
H.C. Wainwright Downgrades Landos Biopharma (LABP) to Neutral
-
Abbvie (ABBV) PT Raised to $195 at Barclays
-
AbbVie (ABBV) to Acquire Landos Biopharma (LABP) for $20.42/Share
-
AbbVie (ABBV) Confirms FDA Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
-
AbbVie (ABBV): FDA approves mirvetuximab soravtansine-gynx
-
Top pharma stocks to own in 2024 – Citi
-
AbbVie (ABBV) Announces JUVEDERM VOLUMA XC For Temple Hollows Receives U.S. FDA Approval
-
AbbVie (ABBV) Pays Milestone to Dragonfly Following Dosing of First Patient in Phase 1 Trial of DF4101/ABBV-303
-
AbbVie (ABBV) partners with OSE Immunotherapeutics to develop Novel Monoclonal Antibody
-
Genmab (GMAB) FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab
-
Abbvie (ABBV) PT Raised to $180 at Evercore ISI
-
AbbVie (ABBV) Selling $15B of Bonds in 7 Parts For M&A - Bloomberg
-
AbbVie (ABBV) and Tentarix Collaborate Over Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
-
AbbVie eyes selling at least $13 billion of bonds to fund M&A, Bloomberg reports
-
AbbVie (ABBV) Appoints Robert A. Michael as CEO
-
AbbVie (ABBV) Declares $1.55 Quarterly Dividend; 3.5% Yield
-
AbbVie (ABBV) Completes Acquisition of ImmunoGen (IMGN)
-
Abbvie (ABBV) PT Raised to $196 at DZ Bank
-
Abbvie (ABBV) PT Raised to $195 at Truist Securities
-
Abbvie (ABBV) PT Raised to $172 at UBS
-
This pharma giant is 'firing on all cylinders' - Piper Sandler
-
Abbvie (ABBV) PT Lowered to $196 at Morgan Stanley
-
Abbvie (ABBV) PT Raised to $195 at BMO Capital
-
Abbvie (ABBV) PT Raised to $180 at Goldman Sachs
-
Abbvie (ABBV) PT Raised to $167 at BofA Securities
-
Abbvie (ABBV) PT Raised to $185 at Barclays
-
AbbVie (ABBV) tops Q4 earnings, revenue consensus estimate
-
AbbVie (ABBV) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY24 EPS Guidance
-
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
-
Payrolls, mega-cap tech earnings, Nvidia - what's moving markets
-
Payrolls, mega-cap tech earnings, Nvidia - what's moving markets
-
AbbVie (ABBV) call put ratio 1 call to 1.8 puts into quarter results and outlook
-
AbbVie (ABBV) February weekly 165 straddle into quarter results
-
William Blair upgrades AbbVie to Outperform ahead of Q4 earnings, citing clear path for growth
-
William Blair Upgrades Abbvie (ABBV) to Outperform, 'Strong Growth Outlook Bolstered by Recent M&A and Subsiding Headwinds'
-
Abbvie (ABBV) PT Raised to $170 at Deutsche Bank
-
Leerink Partners Assumes Abbvie (ABBV) at Market Perform
-
Abbvie (ABBV) PT Raised to $175 at Barclays
-
Abbvie (ABBV) PT Raised to $165 at UBS
-
Increasing unusual call option volume: CYTK ABBV PNC OZK OUST GRAB
-
AbbVie expects Botox to maintain market share as competition heats up
-
AbbVie (ABBV) Launches PRODUODOPA in the EU
-
AbbVie (ABBV) Reports Lutikizumab Showed Positive Results in a Phase 2 Trial
Back to ABBV Stock Lookup
